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ABSTRACT 
Current research had focused on the synthesis of the novel pyrazole ethanone linked compounds with improved biological activity. In this 
synthetic process 1st step was to synthesize the intermediate chalcone and 2nd step was the synthesis of final compound pyrazole derivative 
containing ethanone moiety. This procedure is the type of cyclization reaction using proton transfer mechanism.  By using this method 8 
derivatives synthesized.  After synthesis these were subjected to identification tests by using various methods like melting point study, thin 
layer chromatography, solubility study and characterization by using UV, IR and NMR Spectroscopy.  
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1. INTRODUCTION 
Inflammation is the part of natural defense system of the 
body. It is a process where the cells & natural chemicals of 
the body protect us from physical damage & infection from 
foreign substances such as bacteria & viruses. WBCs or 
leukocytes are the major infection fighting cells of the body. 
The principal objective of inflammation is to isolate, 
localized & eradicate foreign substances & repair damaged 
tissues. In recent years pyrazole derivatives have been a 
topic of interest among the researchers because of their 
pharmacological properties like anti-inflammatory, 
ulcerogenic, antibacterial, diuretic, analgesic, antiviral, 
antifungal, anti-mycobacterial activity etc1. (Rainsford et al., 
2001).  
The inflammatory process includes a series of events that 
can be initiated by numerous stimuli (e.g. infectious agents, 
ischemia, antigen-antibody interaction and thermal or other 
physical injuries). Almost two decades ago, steroids namely 
prednisolone, dexamethasone, betamethasone, etc. were 
considered to be the choicest anti-inflammatory drugs. 
Owing to several adverse effects caused by either short-term 
or long-term steroid therapy, these have been more or less 
replaced by much safer and better-tolerated non-steroidal 
anti-inflammatory drugs (NSAID)2 (Sujatha et al., 2009). 
  Cycloxiginase (COX) enzyme exists in two isomeric forms, 
namely COX-1 and COX-2, while the existence of a third 
isoforom (COX-3) is still into debate. However, recent 
studies have shown that COX-2 inhibitors are associated 
with increased thromboembolic phenomena in speciﬁc 
patient populations such as cardiovascular disease patients 
challenging the beneﬁts of selective COX-2 inhibition. COX-1 
and COX -2 are very similar in  structure and are almost 
identical in length varying from 599 (human) to 602 (mice) 
amino acid in COX -1 and 603 (mice) to 604 (human) for 
COX-2. COX-2 contains an 18 amino acid insert near the C-
terminal end of the enzyme that is not present in COX-1, but 
all other residues that have been previously identified as 
being essential to the catalytic activity of COX-1 are present 
in COX-2. 
A major difference between COX-1 and COX-2 is that COX-2 
lacks a sequence of 17 amino acid from the N-terminus but 
contains a sequence of 18 amino acid at the C-terminus 
compared to COX-1. From a therapeutic viewpoint, the major 
difference between COX-1 and COX-2 lies in physiological 
function rather than structure. The main mediators of 
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inflammation are derivatives of arachidonic acid (AA) which 
is an a unsaturated fatty acid containing 20 carbon chain, 
produced from membrane phospholipids.  
The principal pathways of Arachidonic acid metabolism are:  
 The 5-Lipoxygenase pathway, which produces a 
collection of leukotrienes (LT)   
 The Cyclooxygenase (COX) pathway, which produces 
prostaglandin H2 (PGH2).  
PGH2 is the substrate for two enzymatic pathways, one 
leading to the production of several Prostaglandins (PG); the 
other leading to the production of thromboxanes (Tx).3 
(Dhondge R. et.al, 2009) 
The Non-steroidal anti-inflammatory drugs (NSAIDs) are 
among the most commonly used medications in the world 
(Zarghi et al., 2009a). Their anti-inflammatory activity is due 
to inhibition of cyclooxygenases (COXs), which catalyze the 
bioconversion of arachidonic acid to inflammatory 
prostaglandins (PGs) (Zarghi et al., 2009b). Prostaglandins 
such as PGE2 are produced in the cyclooxygenase pathway 
of the arachidonic acid cascade by the action of the 
isoenzymes COX-1 and COX-2 (Schuhly et al., 2009) 4. 
Prostaglandins are among the most important mediators of 
inflammation. They promote blood vessel dilation and 
vascular permeability, causing the typical redness, heat and 
swelling phenomena involved in inflammation. Moreover, 
they promote pain transmission from nociceptors to the 
brain by increasing the sensitivity of the nerve endings. 
However, prostaglandins also play a cytoprotective role in 
the gastrointestinal tract and they are necessary for normal 
platelet aggregation and renal function (Girgis et al., 2009)5. 
The success of NSAIDs is in the treatment of various 
inflammatory disorders such as inhibition of COX enzyme as 
a target of anti-inflammatory therapies. 
 However, the GI toxicities associated with the use of NSAIDs 
proved to be a major problem during long term therapy 
(Zebardast et al., 2009)6. Side effects such as gastrointestinal 
pain have been associated with NSAID use due to the 
inhibition of COX-1 (Kouatly et al., 2009)7. 
The identification of COX-2 and the subsequent introduction 
of the COX-2 selective inhibitor NSAIDs were thought to be a 
major breakthrough, with the expectation of a significant 
reduction in GI side effects (Sondhi et al., 2008)8. The 
differential tissue distribution of cyclooxygenase-1 (COX-1) 
and cyclooxygenase-2 (COX-2) provides a rationale for the 
development of selective COX-2 inhibitors as anti-
inflammatory-analgesic agents that lack the GI side effects 
exhibited by traditional NSAIDs (Navidpour et al., 2007)9. 
In recent years active research has been initiated on halogen 
containing heterocycles, particularly ﬂuorine and chlorine. 2, 
4-Dichloro-5-ﬂuoroacetophen is used in the synthesis of 
drugs like Ciproﬂoxacin and their analogs. Incorporation of 
ﬂuorine or CF3 group into an organic molecule largely 
enhances the pharmacological properties and also could lead 
to increased lipid solubility, enhancing the rates of 
absorption and transport of drugs in vivo. The replacement 
of hydrogen or hydroxyl group by ﬂuorine. The preliminary 
study towards new potential COX-2 selective compounds as 
novel drug candidates for inﬂammatory and related 
diseases, new introduced systematic modiﬁcations to the 
4,5diphenyloxazolone core structure. It is well established 
that 3,4diaryloxazolones having a sulfone or sulfonamide on 
the 4-phenyl is a good template for selective COX-2 
inhibition. Recently evaluating ester and amide derivatives 
of indomethacin and meclofenamic acid resulted in highly 
potent and selective compounds and it was suggested that 
derivatization of the carboxylate moiety in moderately 
selective COX-1 inhibitors can be used as a novel strategy for 
generation of potent and selective COX2 inhibitors.  
COX-2 selective inhibitors play a role in reducing the 
incidence of GI side effects among NSAIDs are the reports of 
other potential therapeutic uses for this new class of drugs 
including potential use in the treatment of Alzheimer's 
disease and various carcinomas. 
Epidemiological studies suggest a significant reduction in 
the risk for colon cancer in patients regularly taking aspirin. 
NSAIDs have also been reported to reduce the growth rate of 
polyps in the colon in human as well as the incidence of 
tumors of the colon in animals. The effectiveness of NSAIDs 
in the prevention and treatment of other cancers such as 
prostate cancer and mammary carcinoma has also been 
reported.  
Pyrazole represents one of the most active classes of 
compounds possessing wide spectrum of biological 
activities. (Karthikeyan MS et.al, 2009)10 
Current research has focused on developing safer NSAIDs-
selective COX-2 inhibitors  
(Lv et al., 2010)11 by synthesis of new compound that is 
absolutely required for the inhibition or antagonism of the 
abnormalities due to inflammatory response 
1.2 Future prospects 
COX-2 selective inhibitors play a role in reducing the 
incidence of GI side effects among NSAIDs are the reports of 
other potential therapeutic uses for this new class of drugs 
including potential use in the treatment of Alzheimer's 
disease and various carcinomas. 
Epidemiological studies suggest a significant reduction in 
the risk for colon cancer in patients regularly taking aspirin. 
NSAIDs have also been reported to reduce the growth rate of 
polyps in the colon in human as well as the incidence of 
tumors of the colon in animals. The effectiveness of NSAIDs 
in the prevention and treatment of other cancers such as 
prostate cancer and mammary carcinoma has also been 
reported.  
Pyrazole represents one of the most active classes of 
compounds possessing wide spectrum of biological 
activities. Many of the therapeutically useful compounds 
such as Phenylbutazone, Oxyphenbutazone and Antipyrine, 
belong to Pyrazoles. 
2. MATERIALS AND METHODS 
2.1 Synthesis Of Compounds: 
Step 1 General Synthetic Procedure for Chalcones: 
 Equimolar quantities (10mmol, 1equiv) of the aromatic 
aldehydes and substituted acetophenones were dissolved in 
approximately 15 ml of ethanol. The mixture was allowed to 
stir for several minutes at 5-10C. A 10 ml portion of a 40% 
aqueous potassium hydroxide solution was then slowly 
added drop wise to the reaction flask. The reaction solution 
was allowed to stir at room temperature for approximately 4 
hours. Most commonly, a precipitate formed was then 
collected by suction filtration. (Figure 1) 
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Figure 1: Step 1 General Synthetic Procedure for Chalcones 
 
Step 2 Synthesis of pyrazole Derivative 
A solution of chalcone (5mmol) in 30 ml of acetic acid was 
added drop wise to 0.6ml of hydrazine Hydrate (12.5mmol) 
and kept under stirring at 120OC for 24hrs. The mixture was 
then poured into ice-water, obtaining the crude pyrazole 
Derivatives which were recrystallised twice from ethanol. 
(Figure 2) 
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Figure 2: Step 2 Synthesis of pyrazole Derivative 
 
2.2   Synthesis Of Pyrazole Derivatives:    
2.2.1   1-[3-(3, 4-bromophenyl)-5-(4-methoxyphenyl)-4, 
5-dihydro-1h-pyrazole-1-yl] ethanone [KM-1]: 
Anisaldehyde (1.2ml, 10mmol) and 4-bromoacetophenone 
(1.94g, 10mmol) were dissolved in approximately 15 ml of 
ethanol. The mixture was allowed to stir for several minutes 
at 5-10OC. A 10 ml portion of a 40% aqueous potassium 
hydroxide solution was then slowly added drop wise to the 
reaction flask. The reaction solution was allowed to stir at 
room temperature for approximately 4 hrs. Then obtained 
precipitate (Chalcone) was collected by suction filtration. 
 A solution of Chalcone (5mmol) in 30 ml of acetic acid was 
added drop wise to 0.6 ml of hydrazine hydrate (12.5mmol) 
and kept under stirring at 120ºC for 24 hrs. The mixture was 
then poured into ice-water, obtaining the crude pyrazole 
derivatives which were recrystallized twice from ethanol. 
2.2.2   1-[3-(4-bromophenyl)-5-(4-chlorophenyl)-4,5-
dihydro-1h-pyrazole-1-yl] ethanone[KM-2]  
4-Chlorobenzaldehyde (1.40g, 10mmol) and 4-
bromoacetophenone (1.99g, 1-mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
2.2.3   1-[3-(3,4-dimethoxyphenyl)-5-(4-chlorophenyl)-
4,5-dihydro-1h-pyrazole-1-yl] ethanone [KM-3] 
4-Chlorobenzaldehyde (1.40g, 10mmol) and 3,4-
dimethoxyacetophenone (1.80g, 10mmol) were dissolved in 
approximately 15 ml of ethanol the remaining procedure 
was same as used for the compound KM-1. 
2.2.4   1-[3-(4-ethylphenyl)-5-(4-chlorophenyl)-4,5-
dihydro-1h-pyrazole-1-yl]ethanone [KM-4] 
 4-Chlorobenzaldehyde (1.40g, 10mmol) and 4-
ethylacetophenone (1.34g, 10mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
2.2.5   1-[3-(3,4-dimethoxyphenyl)-5-(4-fluororophenyl)-
4,5-dihydro-1h-pyrazole-1-yl] ethanone [KM-5]: 
4-fluorobenzaldehyde (1.24g, 10mmol) and 3,4-
dimethoxyacetophenone (1.80g, 10mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
2.2.6   1-[3-(2-bromo-4-methoxyphenyl)-5-(4-
chlorophenyl)-4,5-dihydro-1h-pyrazole-1-
yl]ethanone [KM-6]: 
4-Chlorobenzaldehyde (1.40g, 10mmol) and 2-bromo-4-
methoxyacetophenone (2.29g, 10mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
2.2.7   1-[3-(4-bromophenyl)-5-(4-fluororophenyl)-4,5-
dihydro-1h-pyrazole-1-yl] ethanone [KM-7]: 
4-fluorobenzaldehyde (1.24g, 10mmol) and 4-
bromoacetophenone (1.99g, 10mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
2.2.8   1-[3-(4-ethylphenyl)-5-(4-fluororophenyl)-4,5-
dihydro-1h-pyrazole-1-yl] ethanone [KM-8]: 
4-fluorobenzaldehyde (1.24g, 10mmol) and 4-
ethylacetophenone (1.34g, 10mmol) were dissolved in 
approximately 15 ml of ethanol and the remaining procedure 
was same as used for the compound KM-1. 
List of synthesized compounds given in table 1 
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N N
O
H3C
R1
R2
 
S. no. Compound code R1 R2 
1 KM-1 4-Br 4-OCH3 
2 KM-2 4-Br 4-Cl 
3 KM-3 3,4-OCH3 4-Cl 
4 KM-4 4-C2H5 4-Cl 
5 KM-5 3,4-OCH3 4-F 
6 KM-6 2-Br, 4-OCH3 4-Cl 
7 KM-7 4-Br 4-F 
8 KM-8 4- C2H5 4-F 
 
2.3 Physiochemical characterization: 
The following tests were performed to check the quality of 
the synthesized compounds. Physicochemical 
characterization of synthesized compounds was done by 
using following various parameters. 
Melting point of synthesized compounds was determined in 
open capillary tube by VEEGO apparatus. Practically 
obtained melting point indicates the purity of synthesized 
compounds. The yield values and melting points of 
synthesized compounds are reported in table 2   
The purity of synthesized compounds was verified by thin 
layar chromatography using silica gel-G as adsorbent and 
Benzene: Petroleum ether: Chloroform (6:2:2) and spots 
were observed when exposed to iodine vapors under iodine 
chamber. The Rf   of synthesized compounds are reported in 
table 2 
 
Table 2:  Physical constant data of synthesized compounds: 
S. No. Compound % Yield Melting Point (C ) Rf Value 
1 KM-1 75.12% 105-110C 0.45 
2 KM-2 55.24% 115C 0.60 
3 KM-3 59.09% 110-115C 0.47 
4 KM-4 50.15% 80-85C 0.53 
5 KM-5 70.13% 115-120C 0.24 
6 KM-6 46.74% 100-105C 0.58 
7 KM-7 65.80% 110-115C 0.61 
8 KM-8 50.65% 110C 0.50 
 
2.3.1 Solubility study: 
Each of the synthesized compounds (2 mg) was transferred 
in 5 ml of different pure solvent and results are reported in 
table 3 
After completion of the synthesis, physicochemical 
characterizations of synthesized compounds have been 
performed. Practically obtained melting points were sharp 
which indicates the purity of the synthesized compounds. 
The result of solubility study shows that all the synthesized 
compounds gives maximum solubility in ethanol, chloroform, 
benzene etc. which confirm that the synthesized compounds 
are semi polar in nature. 
 
Table 3: Solubility studies of the synthesized compounds in different solvents 
S. No. Compound Water Alcohol Acetone Chloroform Benzene Hexane 
1 KM-1 -- ++ +++ ++ ++ + 
2 KM-2 -- ++ +++ ++ ++ + 
3 KM-3 -- ++ +++ ++ ++ + 
4 KM-4 -- ++ +++ ++ ++ + 
5 KM-5 -- ++ +++ ++ ++ + 
6 KM-6 -- ++ +++ ++ ++ + 
7 KM-7 -- ++ +++ ++ ++ + 
8 KM-8 -- ++ +++ ++ ++ + 
+++ Freely soluble                        + sparingly soluble                      ++ Soluble                        - - practically insoluble 
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3 RESULTS AND DISCUSSION 
3.1 Spectroscopy:  
The structural determination of the compounds had been 
done by using UV, IR and NMR spectroscopic methods. For 
determination of max of synthesized compounds, ethanol 
was used as solvent. For UV- spectroscopy, UV SHIMADZU 
1700s Spectrophotometer was used from the sophisticated 
instrument lab of the institution. The obtained UV spectra of 
the compounds KM-1 to KM-8 and their max values were 
given in the table 4 
The IR spectra of synthesized compounds were obtained 
from SAIF, Punjab University, using KBR pellets. IR spectra 
of synthesized compounds were shown characteristic 
absorption for the functional groups present in compounds. 
The Interpretation of IR spectra of synthesized compounds 
given in the table 4. The NMR spectra (Nuclear Magnetic 
Resonance 1H-NMR Spectra) of synthesized compounds 
were obtained from Sophisticated Analytical 
Instrumentation Facility (SAIF), central instrument 
laboratory, Punjab University, Chandigarh on a Burker 
Avance II- 400 MHz NMR spectrometer, Deuteriated 
Chloroform (CDCl3) as a solvent and TMS (Tetra Methyl 
Silane) as internal standard.  NMR spectra of synthesized 
compounds were shown splitting patterns which is 
described as singlet (s), doublet (d), and multiplet (m). NMR 
values are given in chemical shift in ppm. Interpretation of 
NMR spectra of the synthesized  
The NMR was also performed at Punjab University, 
Chandigarh and recorded spectrums were interpreted. 
Spectroscopic data to support the laboratory synthesis of 
compounds KM-1 to KM-8 given in table 4 
 
Table 4: λ max (nm) and NMR data of synthesized compounds 
S No. Compounds UV analysis 
λ max  
 IR interpretation  NMR Interpretation  
1. KM-1 295.0 1658- C=O stretch (s), 3020- C-H stretch 
(m), 1418- C-C stretch (aromatic), 548- C-
Br stretch (m), 1252- C-N stretch (m), 
1514- C-H bend (m) 
1H NMR (CDCl3): δ values 2.36-2.39 (s, 
3H, CH3-CO), 3.14 (m, 3H, O-CH3), 3.66-
3.84 (m, 1H, CH-Br ), 5.53-5.57 (m, 2H, 
CH2),  6.82 -7.61 (m, 8H, Ar) 
2. KM-2 294.5 1658-C=O stretch (s), 3060-C-H stretch 
(m), 1436-C-C stretch(aromatic), 543-C-Br 
stretch (m), 1323-C-N stretch (m), 823-C-
Cl stretch (m), 1483-C-H bend 
1H NMR (CDCl3): δ values  2.40(s, 3H, 
CH3-CO), 3.06- 3.10 (d, 1H, CH-Br), 3.69-
3.75 (m, 1H, CH-Cl), 5.54 (s, 2H, CH2), 7.15-
7.58 (m, 8H, Ar) 
3. KM-3 312.5 1649- C=O stretch (s), 2958- C-H stretch 
(m), 1467- C-C stretch (aromatic), 1323- C-
N stretch (m), 823- C-Cl stretch (m), 1517- 
C-H bend 
1H NMR (CDCl3): δ values  2.42 (s, 3H, 
CH3-CO), 3.07-3.77 (m, 6H, O-CH3), 3.92-
3.96 (m, 1H, CH-Cl),  5.52-5.56 (m, 2H, 
CH2), 6.86-7.43 (m, 8H, Ar ) 
4. KM-4 358.0 1659- C=O stretch (s), 2960- C-H stretch 
(m), 1595- C-C stretch (aromatic), 1247- C-
N stretch (m), 836- C-Cl stretch (m), 1445- 
C-H bend (m) 
1H NMR (CDCl3): δ values 1.25 (m, 3H, 
CH3), 2.66-2.71 (m, 2H, Ar-CH2), 2.41(s, 3H, 
CH3-CO), 3.69-3.77 (m, 1H, CH-Cl), 5.51-
5.56 (m, 2H, CH2),  7.15-7.66 (m, 8H, Ar ) 
5. KM-5 313.5 1664- C=O stretch (s), 3002- C-H stretch 
(m), 1516- C-C stretch(aromatic), 1246- C-
N stretch (m), 1401- C-F stretch, (m), 
1445- C-H bend 
1H NMR (CDCl3): δ values 2.42 (s, 3H, 
CH3-CO), 3.08-3.76 (6H or CH3-O) (m), 
3.92-3.96 (d, 1H, CH-F), 5.54-5.58 (m, 2H, 
CH2), 6.8-7.4 (m, 8H, Ar) 
6. KM-6 264.5 1664- C=O stretch (s), 2960- C-H stretch 
(m), 1504- C-C stretch(aromatic), 1252- C-
N stretch (m), 833- C-Cl stretch (m), 1445- 
C-H bend, 530- C-Br stretch (m) 
1H NMR (CDCl3): δ values 2.1-2.58 (m, 1H, 
CH-Br), 2.69-3.73 (m, 3H or CH3-O), 3.82 (s, 
1H, CH-Cl) (s) , 5.52 (s, 2H, CH2), 6.41-8.09 
(m, 8H, Ar) 
7. KM-7 293.0 1661- C=O stretch (s), 2960- C-H stretch 
(m), 1588- C-C stretch(aromatic), 1218- C-
N stretch (m), 549- C-Br stretch (m), 1445- 
C-H bend, 1394- C-F stretch (m) 
1H NMR (CDCl3): δ values 2.40(CH3-C-O) 
(s), 3.07-3.12 (CH-Br) (m), 3.68-3-3.76 
(CH-F) (m), 5.55-5.59 ( methene) (m), 
6.97-7.61 (Ar-8H) (m) 
8. KM-8 290.0 1661- C=O stretch (s), 2927- C-H stretch 
(m), 1507- C-C  stretch(aromatic), 1218- C-
N stretch (m), 1394- C-F stretch (m), 1427- 
C-H bend 
1H NMR (CDCl3): δ values 2.41(CH3-C-O) 
(s), 6.96-7.67 (Ar-8H), 2.58-2.71(m, 2H, Ar-
CH2),  1.20-1.28 (m, 3H, CH3), 5.53-5.57 (m, 
2H, -CH2), 6.96-7.87 (m, 8H, Ar) 
 
4. PHARMACOLOGICAL SCREENING 
The anti-Inflammatory activity of newly synthesized 
pyrazole derivatives was carried out using Formaldehyde 
induced rat hind paw edema method. In this method, rat hind 
paw edema produced by sub planter injection of 2% 
formaldehyde, and paw volume measured by vernier 
calipers. 
4.1 Method: 
Inhibition of formaldehyde induced inflammation in rat paw 
Animals used: Swiss Albino Rats 
No. of groups: 10 groups 
No. of animals used: 6 animals in each group 
Dose of compound: 50mg/kg  
Dose of standard drug: 10mg/kg (Indomethacin) 
Route of administration: Oral (Suspended in 2% Acacia 
solution) 
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Mice were assigned into 10 groups of 6 animals each. They 
were marked for individual animal identification. The 
animals were deprived of food overnight (allowed free 
access to water ad libitium) and synthetic compounds were 
administered once before 30 minutes the injection of 2% 
formaldehyde. Dose volume not exceeding 0.5ml/100gm 
orally was administered. After 30 minutes of test compound 
administration, 0.1ml of 2%w/v of formaldehyde in normal 
saline was injected in to the sub-planter region of the left 
hind paw of mice. Immediately after the formaldehyde 
injection, the volume of its displacement was measured using 
Vernier Callipers. The reading was recorded at 0, ½ & 3 
hours. The % inhibition of edema was calculated at the end 
of 3 hrs by using the following formula (Winter et al., 1962). 
%inhibition = (1-Vt/Vc)*100 
Vt and Vc is a edema volume in the mice treated with the test 
drug and control respectively 
4.2 Statistical analysis:  
The results are presented as Mean ± SEM (Standard Error 
Mean) of Six Rats. Statistical analysis were performed using 
one way analysis of variance (ANOVA) followed by Dunnett’s 
t-Test for multiple comparisons, Using Graph Pad Software. P 
Values <0.05-0.01 were Considered to be significant, given in 
table 5 figure 3 
 
Table 5: Anti-inflammatory activity (formaldehyde induced rat hind paw edema method) 
 
 
Groups 
 
Dose (mg/kg) 
Mean paw volume(mm) ± SEM and 
% Inhibition (P.I.) 
 
 
% Inhibition 
(1-Vt/Vc)*100 
Time after formaldehyde injection 
Before 
Formaldehyde 
(V0)  
3hrs. 
(Vt)  
I  (Control)        ---- 5.11±0.39 6.85±0.35 ---- 
II (Std.) 10 5.265±0.085 5.40±0.10 88.500 
III (KM-1) 50 5.00±0.60 6.395±0.845 19.820 
IV (KM-2) 50 5.195±0.675 6.35±0.65 33.620 
V (KM-3) 50 5.05±0.05 5.75±0.05 59.770 
VI (KM-4) 50 4.75±0.35 6.125±0.125 20.977 
VII (KM-5) 50 5.23±0.31 5.5±0.30 84.850 
VIII (KM-6) 50 5±0.70 5.75±0.55 56.890 
IX (KM-7) 50 5.505±0.205 6.12±0.62 64.655 
X (KM-8) 50 5.65±0.25 6.10±0.25 74.130 
(n= 6 albino rats per groups; values are represent mean ± SEM; probability value with respect to control group *P<0.01 
considered to be significant) 
 
 
Figure 3: Graph representing % inhibitions of the compounds 
 
Acute inflammation induced by formaldehyde results from 
cell damage, which provokes the production of endogenous 
mediators, such as, histamine, serotonin, prostaglandins, and 
bradykinin. Indomethacin gave more or less uniform 
inhibition of edema in early intermediate and later phases. 
Compound KM-5 showed less significant inhibition of 
formaldehyde induced edema in early phases while 
significant inhibition at later phases. Out of other remaining 
compounds Compound KM-5 was more significant than the 
other compound in percentage inhibition of paw edema, as 
some of the above compounds significantly inhibited this 
model of inflammation. 
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5. CONCLUSION 
The initial postulate that a selective COX-2 inhibitor would 
reduce inflammation without causing gastric irritation was 
validated following the introduction of selective COX-2 
inhibitors such as celecoxib and rofecoxib. However, it was 
subsequently observed that selective COX-2 inhibitors may 
alter the balance in the Cyclooxygenase pathway resulting in 
a decrease in the level of the vasodilatory and anti-
aggregatory prostacyclin (PGI2), relative to an increase in 
the level of the prothrombotic thromboxane A2 (TxA2), 
leading to increased incidences of an adverse cardiovascular 
thrombotic event. COX-2 selective inhibitors play a role in 
reducing the incidence of GI side effects among NSAIDs are 
the reports of other potential therapeutic uses for this new 
class of drugs including potential use in the treatment of 
Alzheimer's disease and various carcinomas.  
Pyrazole represents one of the most active classes of 
compounds possessing wide spectrum of biological activities. 
Many of the therapeutically useful compounds such as 
phenylbutazone, Oxyphenbutazone and antipyrine, belong to 
pyrazoles. 
My current research work had focused on the synthesis of 
the novel pyrazole ethanone linked compounds with 
improved biological activity. The 2 step synthesis of pyrazole 
derivatives was done into the pharmaceutical laboratory 
facility provided by the institute under the guidance of my 
supervisor. In this synthetic process 1st step was to 
synthesize the intermediate chalcone and 2nd step was the 
synthesis of final compound pyrazole derivative containing 
ethanone moiety. This procedure is the type of cyclization 
reaction using proton transfer mechanism.  By using this 
method I synthesized 8 derivatives as given below: 
1. 1-[3-(3,4-Bromophenyl)-5-(4-Methoxyphenyl)-4,5-
dihydro-1H-Pyrazole-1-yl]Ethanone [KM-1] 
2. 1-[3-(4-Bromophenyl)-5-(4-chlorophenyl)-4,5-
dihydro-1H-Pyrazole-1-yl] Ethanone[KM-2] 
3. 1-[3-(3,4-Dimethoxyphenyl)-5-(4-chlorophenyl)-4,5-
dihydro-1H-Pyrazole-1-yl] Ethanone [KM-3] 
4. 1-[3-(4-Ethylphenyl)-5-(4-chlorophenyl)-4,5-dihydro-
1H-Pyrazole-1-yl]Ethanone[KM-4] 
5. 1-[3-(3,4-Dimethoxyphenyl)-5-(4-fluororophenyl)-4,5-
dihydro-1H-Pyrazole-1-yl] Ethanone [KM-5] 
6. 1-[3-(2-Bromo-4-methoxyphenyl)-5-(4-chlorophenyl)-
4,5-dihydro-1H-Pyrazole-1-yl Ethanone  [KM-6] 
7. 1-[3-(4-Bromophenyl)-5-(4-Fluororophenyl)-4,5-
dihydro-1H-Pyrazole-1-yl]Ethanone [KM-7] 
8. 1-[3-(4-Ethylphenyl)-5-(4-Fluororophenyl)-4,5-
dihydro-1H-Pyrazole-1-yl]Ethanone [KM-8] 
All these compounds were synthesized and after synthesis 
these were subjected to identification tests by using various 
methods like melting point study, thin layer 
chromatography, solubility study and characterization by 
using UV, IR and NMR Spectroscopy. All the data of 
compounds confirms the synthesis of the above mentioned 
derivatives. Like melting point of all the pyrazole derivatives 
ranges between 80-120C, the thin layer chromatography by 
using  silica gel-G as adsorbent and benzene: petroleum 
ether: chloroform (6:2:2) as a solvent system, solubility data 
represents that the synthesized compounds were semi polar 
in nature like it is insoluble in water soluble in ethanol, 
acetone, chloroform and sparingly soluble in hexane.  
The UV spectroscopic data represents the λmax (nm) values of 
the compounds. IR spectroscopy helps to identify the 
chemical structure of the compounds, like in the given data 
all the compounds show the peak values of the representing 
group which is present in the compounds so here all these 
pyrazole derivatives show C=O stretch, C-H stretch, C-C 
stretch (aromatic), C-Br stretch, C-N stretch, C-H bend, C-Cl 
stretch, C-F stretch peaks that confirms the structure of the 
pyrazole derivatives.  
NMR spectroscopic data also helps to confirm the presence 
of hydrogen bonds in the compound so here the NMR 
spectroscopy was done by using CDCl3 as the solvent and 
tetra methyl silane as the internal standard and the chemical 
shift values (ppm) gave the much more conformation about 
the structural determination of the compound that it 
contains pyrazole ring with ethanone skeleton and 2 
neighboring substituted benzene rings given in figure. 
After structural determination the in-vivo testing of the 
synthesized compounds also had been done by using 
Formaldehyde-induced rat hind paw edema method in which 
swiss albino rats were used for animal model, 2% 
formaldehyde solution (for induction of inflammation in 
animals), indomethacin (NSAID) in a dose of 10mg/kg body 
weight, and for test compounds 50mg/kg body weight, 
method includes 10 groups on which this study was taken 
place as control, standard, and 8 test compound groups. % 
inhibition values were represented as mean ± SEM.   
All the above given data summarizes that among all the 
synthesized compounds KM-5 gave  84% inhibition of 
inflammation, while the standard drug (indomethacin) 
shows 88.5% inhibition of the inflammation. Thus it can be 
concluded that the compound KM-5 is active and belongs to 
the class of COX-2 inhibitory anti-inflammatory agents. 
(Figures: 4,5,6) 
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Figure 4: representing the synthesized basic synthesized 
pyrazole nucleus 
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Figure 5:  Chemical structure of the synthesized compound 
KM-5  
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Figure 6: Chemical structure of the synthesized compound 
Indomethacin. 
ACKNOWLEDGMENT 
Authors are thankful to Head, department of Pharmaceutical 
Science, V.N.S. Institute of Pharmacy, Bhopal (M.P.) for 
providing necessary facilities.  
REFERENCES 
1. Rainsford KD. The Ever emerging Anti-inflammatory Journal of 
Physiology Paris, 2001; 95:11-19. 
2. Sujatha K and Perumal PT and Muralidharan D and Rajendran 
M. Synthesis, analgesic and anti-inflammatory activities of 
bis(indolyl)methanes” Indian Journal of Chemistry,  2009; 
48:267-272. 
3. Dhondge R and Chaturvedi SC. QSAR analysis of 2-
sulfonylphenyl-3-phenyl-indole derivatives as novel anti-
inflammatory compounds Medicinal Chemistry Research 2009; 
18:167-178. 
4. Zarghi A and Ghodsi R and Azizi E and Daraie B and Hedayati M 
and Dadrass OG. Synthesis and biological evaluation of new 4-
carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors 
Bioorganic & Medicinal Chemistry, 2009b; 17:5312. 
5. Schuhly W and Hufner A and Pferschy-Wenzig EM and Prettner 
E and Adams M and Bodensieck A and Kunert O and  
Oluwemimo A and Haslinger E and Bauer R.  Design and 
synthesis of ten biphenyl-neolignan derivatives and there in 
vitro inhibitory potency against cyclooxygenase-1/2 activity 
and 5-lipoxygenase-mediated LTB4-formation Bioorganic & 
Medicinal Chemistry, 2009; 17:4459-4465. 
6. Girgis AS and Barsoum FF. Synthesis of [1, 2, 4]triazolo[1,5-
a]pyridines of potential PGE2 inhibitory properties European 
Journal of Medicinal Chemistry, 2009; 44:1972-1977.  
7. Kouatly O and Geronikaki A and  Kamoutsis C and Hadjipavlou-
Litina D and Eleftheriou P. Adamantane derivatives of thiazolyl-
N-substituted amide, as possible non-steroidal anti-
inflammatory agents European Journal of  Medicinal  
Chemistry, 2009;  44:1198-1204.  
8. Sondhi SM and Dinodia M and Jain S and Kumar A. Synthesis of 
biologically active N-methyl derivatives of amidines and 
cyclized five-membered products of amidines with oxalyl 
chloride European Journal of  Medicinal Chemistry 2008; 
43:2824-2830.  
9. Navidpour L and Shadnia H and Shafaroodi H and Amini M and 
Dehpourd AR and Shafieea A. Design, synthesis and biological 
evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as 
selective COX-2 inhibitors Bioorganic & Medicinal Chemistry 
2007; 15:1976-1982.  
10. Karthikeyan MS. Synthesis, analgesic, anti-inﬂammatory and 
antimicrobial studies of 2,4-dichloro-5-ﬂuorophenyl containing 
thiazolotriazoles European Journal of Medicinal Chemistry,  
2009; 44:827-833. 
11. Lv P and  Li H and  Juan S and Yang Z and Zhu H. Synthesis and 
biological evaluation of pyrazole derivatives containing 
thiourea skeleton as anticancer agents Bioorganic & Medicinal 
Chemistry 2010; 18 (1):4606-4614. 
 
 
